Observational studyBlood transfusion = Trasfusione del sangue
Effectiveness of oral platelet lysate gel to treat oral mucosal manifestations associated with chronic graft versus host disease.
Observational study in Blood transfusion = Trasfusione del sangue. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Platelet Lysate-Based Biomaterials for Regenerative Tissue Engineering: A Comprehensive Review.International journal of nanomedicine · 2026Review
- Cord Blood-Derived Platelet Gel in Wound Healing: From Biological Rationale to Clinical Application.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair SocietyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic graft-vs-host disease (cGvHD) is a severe immune-mediated complication that affects patients following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Oral manifestations of cGvHD, such as ulcers and mucosal inflammation, significantly impair quality of life and often require long-term treatment. Existing therapies provide limited relief, prompting the exploration of new approaches, including the use of autologous platelet lysate (PL) gel for its regenerative properties. MATERIALS AND
methodsThis observational study evaluated the effectiveness and safety of a topical autologous PL gel in treating oral ulcers associated with cGvHD in seven patients who had undergone allo-HSCT for hematological malignancies. The PL gel was prepared by mixing autologous PL with a gel base under aseptic conditions, and patients applied the gel three times daily. Clinical assessments, including the severity of oral damage and pain levels, were conducted using the NIH-CTCAE scale.
resultsOf the seven patients treated, five completed the study with a median follow-up of 20 months. Significant reductions in oral damage severity and pain levels were observed, with a p-value of 0.0495 for symptom severity and 0.0196 for pain reduction. The average adherence rate was 81.4%, and no adverse effects were reported. DISCUSSION: The study demonstrated that autologous PL gel is a promising and well-tolerated treatment for oral manifestations of cGvHD, offering significant symptom relief. Despite the small sample size, these findings align with previous studies and support further research into PL gel as a therapeutic option in cGvHD management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.